Related references
Note: Only part of the references are listed.Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matthias S. Matter et al.
JOURNAL OF HEPATOLOGY (2014)
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment
A. Casazza et al.
ONCOGENE (2014)
c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1α
Cheng Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
Christopher Daly et al.
CANCER RESEARCH (2013)
PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2
Chi-Tan Hu et al.
CELLULAR SIGNALLING (2013)
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Virginia Hernandez-Gea et al.
GASTROENTEROLOGY (2013)
Hepatic stellate cells in liver development, regeneration, and cancer
Chunyue Yin et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-κB pathways induced by paracrine cytokines
Yao-Hui Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
Maria Vittoria Dieci et al.
CANCER DISCOVERY (2013)
Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2012)
Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: Mechanisms of PDGF-BB-mediated VSMC proliferation and migration
Nor Saadah M. Azahri et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY
J. M. Llovet et al.
JOURNAL OF HEPATOLOGY (2012)
The role of dystroglycan in PDGF-BB-dependent migration of activated hepatic stellate cells/myofibroblasts
George John Kastanis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
Christopher Lieu et al.
CLINICAL CANCER RESEARCH (2011)
Up-Regulation of the Fibroblast Growth Factor 8 Subfamily in Human Hepatocellular Carcinoma for Cell Survival and Neoangiogenesis
Christine Gauglhofer et al.
HEPATOLOGY (2011)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
Vito Guagnano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer
Johannes Taeger et al.
MOLECULAR CANCER THERAPEUTICS (2011)
HCC and angiogenesis: possible targets and future directions
Andrew X. Zhu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Reduced Expression of Fibroblast Growth Factor Receptor 2IIIb in Hepatocellular Carcinoma Induces a More Aggressive Growth
Thomas Amann et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
Sven A. Lang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
The Significance of Fibroblast Growth Factor Receptor 2 Expression in Differentiation of Hepatocellular Carcinoma
Norifumi Harimoto et al.
ONCOLOGY (2010)
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma
Thomas Amann et al.
CANCER SCIENCE (2009)
Targeting Heat-Shock Protein 90 Improves Efficacy of Rapamycin in a Model of Hepatocellular Carcinoma in Mice
Sven A. Lang et al.
HEPATOLOGY (2009)
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
Hung Huynh et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies
Ronnie T. P. Poon et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model
Sven A. Lang et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Murine models to evaluate novel and conventional therapeutic strategies for cancer
James E. Talmadge et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma
RTP Poon et al.
AMERICAN JOURNAL OF SURGERY (2001)